# Spain Allergy Immunotherapy Market > Spain Allergy Immunotherapy Market Research Report: By Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy, Oral Immunotherapy), By Product (Allergen Extracts, Conventional Immunotherapy, Biologics), By Indication (Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, Food Allergies) andBy Patient Type (Pediatric, Adult, Geriatric)- Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.43% - **2018:** $ 133 Million - **2024:** $ 79.24 Million - **2035:** $ 213.56 Million - **Key Players:** Allergopharma (DE), Anergis (CH), ALK-Abello (DK), Boehringer Ingelheim (DE), Merck Group (DE), Stallergenes Greer (FR), Novartis (CH), Sanofi (FR), UCB (BE) **Report ID:** MRFR/HC/54533-HCR · **Pages:** 200 · **Author:** Nidhi Mandole · **Last Updated:** March 28, 2026 **URL:** https://www.marketresearchfuture.com/reports/spain-allergy-immunotherapy-market-56299 --- ## Market Summary **Spain Allergy Immunotherapy Market Overview****:** **As per MRFR analysis, the Spain Allergy Immunotherapy Market Size was estimated at 133 (USD Million) in 2023. The Spain Allergy Immunotherapy Market Industry is expected to grow from 142.75(USD Million) in 2024 to 356.88 (USD Million) by 2035. The Spain Allergy Immunotherapy Market CAGR (growth rate) is expected to be around 8.687% during the forecast period (2025 - 2035).** **Key Spain Allergy Immunotherapy Market Trends Highlighted** Several significant trends are being influenced by the health policies and consumer awareness of Spain Allergy Immunotherapy Market. There is a growing demand for immunotherapy treatments in Spain due to the rising incidence of allergic diseases, which is influenced by environmental factors and lifestyle changes. Due to the Spanish healthcare system's acknowledgment of allergies as a significant public health issue, there has been an increase in funding for research and development of immunotherapy solutions. Additionally, the increased awareness of immunotherapy's advantages among patients facilitates early diagnosis and treatment. There is a growing emphasis on personalized medicine, which involves the development of remedies that are specifically tailored to the unique characteristics of each patient. Spain's healthcare initiatives prioritize patient-centered care, which is consistent with this approach. This is accompanied by the increasing prominence of technology in the administration of treatment, such as mobile health applications that facilitate the monitoring of symptoms and the progression of treatment. This trend improves treatment adherence and patient engagement. In rural areas of Spain, there are opportunities to increase access to immunotherapy, as there are still many regions with inadequate healthcare resources. To enhance patient outcomes, it is also essential to invest in the training of healthcare professionals on the most recent immunotherapy advancements. In addition, pharmaceutical companies and research institutions in Spain are currently engaged in ongoing collaborations to develop and innovate new therapies that have the potential to capture an increasing market segment.Given the ongoing increase in allergic reactions and the societal demand for effective treatments, the Spain Allergy Immunotherapy Market is poised for substantial growth in the years ahead, thereby satisfying the healthcare requirements of its population. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Spain Allergy Immunotherapy Market Drivers** Increasing Allergy Prevalence in Spain The Spain Allergy Immunotherapy Market Industry is significantly driven by the rising prevalence of allergic diseases among the population. Recent studies indicate that over 30% of the Spanish population suffers from at least one type of allergy. The Spanish Ministry of Health reported that respiratory allergies, such as allergic rhinitis and asthma, have been increasing at an alarming rate, with a jump of more than 20% in asthma cases over the past decade.Furthermore, organizations like the Spanish Society of Allergology and Clinical Immunology (SEAIC) highlight that this surge is largely due to changes in environmental factors and lifestyle, which contribute to an increase in allergenic stimuli. This escalating condition prompts a greater demand for allergy treatments, particularly immunotherapy, positioning it as a favorable growth factor in the Spain Allergy Immunotherapy Market. Advancements in Immunotherapy Techniques The advancement of immunotherapy techniques is a crucial driver for the growth of the Spain Allergy Immunotherapy Market Industry. Recent innovations, including sublingual immunotherapy and enhanced injection methods, have improved patient compliance and therapy efficacy. The Spanish government has funded various Research and Development (R&D) initiatives aimed at refining these techniques, leading to a reported increase in treatment success rates by up to 65%.Additionally, clinical trials spearheaded by leading organizations, such as the Spanish Agency of Medicines and Medical Devices (AEMPS), promote new therapies that cater to a broad range of allergens, encouraging growth within this market segment. Government Initiatives to Combat Allergic Conditions The Spain Allergy Immunotherapy Market Industry is also positively influenced by governmental initiatives aimed at raising awareness and combating allergic conditions. The Ministry of Health in Spain has launched campaigns to educate the public about allergies and available treatments, increasing patient engagement and access to immunotherapy options. In 2020, public health policies directed approximately EUR 5 million toward projects aimed at improving allergy diagnostics and treatment facilities throughout the country.This backing not only enhances the public’s understanding of allergen management but also boosts the overall market for immunotherapy solutions, thus contributing significantly to its anticipated growth. **Spain Allergy Immunotherapy Market Segment Insights****:** **Allergy Immunotherapy Market Type Insights** The Spain Allergy Immunotherapy Market is characterized by its diverse Type segmentation, which includes Subcutaneous Immunotherapy, Sublingual Immunotherapy, and Oral Immunotherapy. Each of these types plays a critical role in addressing allergy treatment needs across the country. Subcutaneous Immunotherapy, often referred to as allergy shots, has been a longstanding approach, delivering doses of allergens via injection, thus benefiting patients with a robust and controlled method of desensitization. It is particularly prominent among individuals dealing with severe allergic reactions, as it allows for a gradual decrease in symptoms over time. On the other hand, Sublingual Immunotherapy has gained traction in Spain due to its ease of administration and favorable patient compliance. This method involves placing allergen tablets or drops under the tongue, offering a non-invasive, at-home treatment option that appeals to a younger demographic and busy families. The growing acceptance of Sublingual Immunotherapy indicates a shift towards more patient-centric care, facilitating better adherence compared to traditional methods. Additionally, Oral Immunotherapy represents an emerging frontier within the Spain Allergy Immunotherapy Market. This form of treatment is particularly appealing for its potential in the long-term management of food allergies. Allowing patients to ingest small, controlled amounts of an allergen fosters a gradual building of tolerance, which can significantly enhance quality of life. The evolution of these various types of immunotherapy is driven by increasing awareness of allergies in Spain and the growing demand for effective treatments, supported by the Spanish Ministry of Health's initiatives to improve allergy management and patient education. Considering the ongoing advancements in technology and research, the Spain Allergy Immunotherapy Market reflects a promising landscape shaped by an increasing prevalence of allergic disorders, resulting in a higher-than-average incidence rate in adults and children alike. In recent years, there has been a noticeable trend towards personalized medicine, which further encourages research into type-specific allergy treatments suited to the unique sensitivities of the Spanish population. As innovation and education continue to grow within this sector, the alignment of treatment methods with patient preferences and lifestyle choices remains a crucial factor in ensuring superior outcomes for allergy sufferers across Spain. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Allergy Immunotherapy Market Product Insights** The Spain Allergy Immunotherapy Market demonstrates significant growth within its Product segment, which includes Allergen Extracts, Conventional Immunotherapy, and Biologics. Allergen Extracts hold a prominent position, often considered a fundamental component of allergy treatment due to their role in desensitization, making them essential in managing allergic reactions across diverse populations in Spain. Conventional Immunotherapy remains a widely utilized method, favored for its long-established efficacy and safety profile, thus contributing to a favorable environment for patient adherence.Meanwhile, Biologics have emerged as an innovative alternative, showing promise, particularly for severely allergic patients unresponsive to traditional therapies. The increasing prevalence of allergic conditions in Spain, coupled with rising awareness and advancements in immunotherapy techniques, drives growth in this market segment. Additionally, ongoing Research and Development initiatives aim to refine these products and enhance their therapeutic outcomes while regulatory support lays a robust framework for market expansion. The combination of traditional and modern approaches in the Product segment underscores a comprehensive strategy to tackle allergies effectively in Spain. **Allergy Immunotherapy Market Indication Insights** The Spain Allergy Immunotherapy Market is characterized by a diverse range of indications, which play a crucial role in addressing the growing burden of allergic conditions in the region. Among these indications, Allergic Rhinitis is particularly significant, affecting a substantial portion of the population and leading to increased healthcare costs. Allergic Asthma also features prominently, as it not only impairs quality of life but poses serious respiratory challenges. Furthermore, Atopic Dermatitis is gaining attention due to its rising prevalence, especially among children, highlighting the need for effective treatment solutions.Food Allergies present an emerging concern, necessitating innovative approaches to management and prevention. This market's segmentation underscores the varying needs of patients and the importance of targeted immunotherapy solutions. With an increasing awareness of allergy management and evolving treatment methodologies, especially in a country like Spain, where allergy-related issues are prevalent, this segment is poised for significant growth as it addresses both immediate and chronic allergic conditions effectively. **Allergy Immunotherapy Market Patient Type Insights** The Spain Allergy Immunotherapy Market exhibits a notable division by Patient Type, encompassing various demographics, including Pediatric, Adult, and Geriatric populations. The Pediatric segment is increasingly important due to the rising incidence of allergic conditions in children, prompting early intervention and treatment strategies. Adults make up a substantial portion of the market, often dealing with chronic allergies that impact their quality of life and productivity, hence driving demand for effective immunotherapy options. The Geriatric segment is also significant, as older adults are more likely to experience allergies exacerbated by health conditions and sensitivities that develop with age.This demographic shift emphasizes the need for tailored allergy treatments that consider the unique physiological characteristics of each age group. Overall, the segmentation within the Spain Allergy Immunotherapy Market reflects the varying needs and treatment responses of different patient groups, aligning with ongoing healthcare initiatives aimed at improving the management of allergic diseases across diverse populations. Furthermore, as the country invests in healthcare improvements, the demand for personalized immunotherapy solutions is likely to enhance treatment outcomes for all age segments, fostering a comprehensive approach to allergy management in Spain. **Spain Allergy Immunotherapy Market Key Players and Competitive Insights****:** The Spain Allergy Immunotherapy Market has witnessed significant growth in recent years due to an increasing prevalence of allergic conditions and a heightened awareness among the population regarding treatment options. The presence of several key players, innovative therapeutic approaches, and advances in immunotherapy techniques characterizes this market. With an increasing number of individuals seeking alternative treatment methods for allergies, competition within the market has intensified. Companies are focusing on developing and expanding their portfolios, as well as enhancing their distribution networks to maintain a competitive edge. The regulatory landscape and healthcare policies in Spain also play a crucial role in shaping market dynamics and influencing the strategies of companies operating within this arena.Stallergenes Greer has established a strong foothold in the Spain Allergy Immunotherapy Market, benefiting from its extensive range of allergen immunotherapy products and a well-recognized brand presence. The company's strength lies in its focus on research and development, enabling it to introduce innovative therapies that cater specifically to the needs of patients suffering from allergic rhinitis, asthma, and other related conditions. Stallergenes Greer has built a reputation for delivering high-quality allergen-specific immunotherapies, and its commitment to clinical excellence has fostered strong trust among healthcare professionals and patients alike. The firm continually invests in educational initiatives and collaborations with local health organizations, further enhancing its visibility and influence in the Spanish market.MediFleur operates within the Spain Allergy Immunotherapy Market with a specialized focus on providing a range of allergy solutions tailored to the local population's needs. The company is noted for its strong product lineup that includes both sublingual and subcutaneous immunotherapy options, addressing various types of allergies effectively. MediFleur's market presence in Spain has been bolstered through strategic partnerships and collaborations with healthcare providers, ensuring its offerings are readily accessible to patients seeking relief from allergy symptoms. The firm has demonstrated a keen eye for innovation, continually expanding its portfolio to include cutting-edge treatments backed by robust clinical research. Additionally, MediFleur has engaged in several mergers and acquisitions, strengthening its market position and enhancing its research capabilities, enabling it to provide comprehensive solutions in the Spanish allergy immunotherapy landscape. **Key Companies in the Spain Allergy Immunotherapy Market Include:** Stallergenes Greer MediFleur Vaccinex Boehringer Ingelheim Romer Labs Novartis AG Astellas Pharma Inc. Regeneron Pharmaceuticals Dr. Reddy's Laboratories Anergis SA Biocryst Pharmaceuticals Merck KGaA Allergopharma GmbH & Co. KG GSK **Spain Allergy Immunotherapy Market Industry Developments** _In recent months, the Spain Allergy Immunotherapy Market has seen significant developments, particularly with the increased focus on environmental allergies and the government’s investment in healthcare innovation. In October 2023, Stallergenes Greer announced the expansion of its allergy immunotherapy production facility in Spain to meet rising demand, supporting local manufacturing and job creation. Additionally, in September 2023, Regeneron Pharmaceuticals and Novartis AG collaborated on a new treatment protocol aimed at enhancing the effectiveness of immunotherapy for allergic patients. In terms of mergers and acquisitions, MediFleur was reported to have acquired certain assets related to allergy diagnostics from Allergopharma GmbH & Co. KG in August 2023, enhancing their market position in Spain. Moreover, the market is witnessing growth, propelled by an increase in allergy prevalence among the Spanish population, particularly in urban areas, leading to heightened awareness and consumption of immunotherapy treatments. Recent trends indicate a consistent rise in market valuation, with companies like Merck KGaA and GSK exploring partnerships to innovate in allergen-specific immunotherapy. Overall, the market is evolving, reflecting a stronger emphasis on tailored therapeutic solutions for allergy sufferers in Spain._ **Spain Allergy Immunotherapy Market Segmentation Insights** **Allergy Immunotherapy Market Type****Outlook** **Subcutaneous Immunotherapy** **Sublingual Immunotherapy** **Oral Immunotherapy** **Allergy Immunotherapy Market Product****Outlook** **Allergen Extracts** **Conventional Immunotherapy** **Biologics** **Allergy Immunotherapy Market Indication****Outlook** **Allergic Rhinitis** **Allergic Asthma** **Atopic Dermatitis** **Food Allergies** **Allergy Immunotherapy Market Patient Type****Outlook** **Pediatric** **Adult** **Geriatric** **** ## Market Drivers ### Supportive Healthcare Policies Supportive healthcare policies in Spain are fostering growth in the [Allergy Immunotherapy](https://www.marketresearchfuture.com/reports/allergy-immunotherapy-market-1517) Market. The Spanish government has been implementing policies aimed at improving access to allergy treatments, including immunotherapy. Initiatives such as subsidized treatment costs and increased insurance coverage for allergy therapies are making immunotherapy more accessible to patients. In 2025, it was reported that over 60% of health insurance plans in Spain included coverage for immunotherapy, which is likely to encourage more patients to seek treatment. This supportive regulatory environment is expected to drive market expansion by reducing financial barriers and promoting the adoption of immunotherapy. ### Emergence of Personalized Medicine The emergence of personalized medicine is transforming the Spain Allergy Immunotherapy Market. Advances in genetic and molecular research are enabling the development of tailored immunotherapy treatments that cater to individual patient profiles. This shift towards personalized approaches is likely to enhance treatment efficacy and patient satisfaction. In 2025, several Spanish research institutions reported breakthroughs in identifying specific allergens at the molecular level, paving the way for customized immunotherapy solutions. As personalized medicine gains traction, it is expected to attract more patients to immunotherapy, thereby driving market growth and innovation in the Spain Allergy Immunotherapy Market. ### Rising Awareness of Allergy Treatments The growing awareness regarding allergy treatments among the Spanish population is a notable driver for the Spain Allergy Immunotherapy Market. Educational campaigns and initiatives by healthcare professionals have led to increased recognition of allergy symptoms and the benefits of immunotherapy. As a result, more patients are seeking treatment options, contributing to market growth. In 2025, it was estimated that approximately 30% of the Spanish population suffered from allergic conditions, highlighting the potential patient base for immunotherapy. This rising awareness is likely to encourage healthcare providers to offer immunotherapy as a viable treatment option, thereby expanding the market further. ### Growing Incidence of Respiratory Allergies The increasing incidence of respiratory allergies, such as allergic rhinitis and asthma, is a significant driver for the Spain Allergy Immunotherapy Market. Data from the Spanish Society of Allergology and Clinical Immunology indicates that around 20% of the population suffers from allergic rhinitis, with numbers steadily rising. This trend is likely to propel demand for immunotherapy as a long-term solution. The growing burden of respiratory allergies on public health systems may prompt healthcare authorities to promote immunotherapy as a cost-effective treatment option, thereby enhancing market prospects. The correlation between rising allergy cases and the demand for immunotherapy is becoming increasingly evident. ### Increased Investment in Research and Development Investment in research and development (R&D) within the Spain Allergy Immunotherapy Market is a critical driver. The Spanish government, alongside private entities, has been allocating substantial funds towards the development of innovative immunotherapy solutions. In 2025, R&D expenditure in the healthcare sector reached approximately 2.5 billion euros, with a significant portion directed towards allergy treatments. This investment is expected to yield new therapies and improve existing ones, enhancing the efficacy and safety of immunotherapy. As new products enter the market, competition will likely intensify, further stimulating growth in the Spain Allergy Immunotherapy Market. ## Future Outlook The Spain Allergy Immunotherapy Market is projected to grow at a 9.43% CAGR from 2024 to 2035, driven by increasing allergy prevalence, technological advancements, and rising healthcare expenditure. **New opportunities:** - Development of personalized immunotherapy solutions for specific allergens. - Expansion of telehealth services for remote allergy consultations. - Investment in AI-driven diagnostic tools for allergy identification. By 2035, the market is expected to be robust, reflecting substantial growth and innovation. ## Segment Insights ### By Application: Allergic Rhinitis (Largest) vs. Allergic Asthma (Fastest-Growing) In the Spain Allergy Immunotherapy Market, allergic rhinitis emerges as the largest application segment, capturing a significant portion of the market share. Allergic rhinitis affects a large demographic, significantly driven by environmental factors, which makes it the predominant condition treated through immunotherapy. In contrast, allergic asthma is witnessing rapid growth, owing to an increasing awareness of the disease and a rising prevalence of asthma among the youth in Spain. The growth trends in this market segment reveal a strong shift towards personalized treatment approaches for allergic asthma, attributed to advancements in medical technology and innovative therapeutics. The emphasis on early diagnosis and the growing public health initiatives aimed at controlling respiratory diseases further bolster the demand for immunotherapy, positioning allergic asthma as the fastest-growing segment in Spain's allergy landscape. Allergic Rhinitis (Dominant) vs. Allergic Asthma (Emerging) Allergic rhinitis is recognized as the dominant application in the Spain Allergy Immunotherapy Market, largely due to its high prevalence and impact on daily living for millions. Characterized by symptoms such as sneezing, runny nose, and itchy eyes, allergic rhinitis is primarily triggered by allergens like pollen, dust mites, and pet dander. On the other hand, allergic asthma is emerging as a significant concern, especially as awareness of respiratory allergies grows. Treatments for allergic asthma have seen rapid advancements, with a focus on addressing both allergic reactions and underlying asthma symptoms. This evolution in treatment is enhancing the market landscape, allowing providers to cater to a broader spectrum of patients seeking relief from respiratory allergies. ### By Type of Immunotherapy: Subcutaneous Immunotherapy (Largest) vs. Sublingual Immunotherapy (Fastest-Growing) In the Spain Allergy Immunotherapy Market, Subcutaneous Immunotherapy holds the largest market share, primarily due to its long-established efficacy and widespread acceptance among healthcare professionals. This method involves administering allergen extracts via injections, which has proven effective for various allergic conditions. On the other hand, Sublingual Immunotherapy is emerging as a formidable competitor, making significant strides in market share, especially among patients seeking a more convenient alternative to injections. Subcutaneous Immunotherapy (Dominant) vs. Sublingual Immunotherapy (Emerging) Subcutaneous Immunotherapy has been the cornerstone of [allergy treatment](https://www.marketresearchfuture.com/reports/allergy-treatment-market-11156) for years, favored for its comprehensive approach towards allergy desensitization through gradual exposure to allergens. It is widely recognized for its ability to provide long-term relief. Conversely, Sublingual Immunotherapy, while newer, is rapidly gaining traction due to its non-invasive nature and ease of administration, making it particularly appealing to patients who may be hesitant about injections. As awareness grows, this segment is poised for significant expansion, reflecting changing patient preferences and an increasing demand for alternative therapy options. ### By Patient Demographics: Children (Largest) vs. Adults (Fastest-Growing) In the Spain Allergy Immunotherapy Market, children represent the largest segment, capturing a significant share of the overall patient demographics. Their higher susceptibility to allergens and environmental factors has led to an increased demand for effective immunotherapy solutions tailored specifically for pediatric patients. As awareness about allergy treatments grows among parents, this segment continues to dominate the market landscape, driving a substantial portion of service utilization in clinics and hospitals. In contrast, adults are witnessing a rapid increase in their segment share, largely due to rising allergen exposure and lifestyle changes. This shift represents an emerging trend where adult immunotherapy options are becoming more recognized and sought after, marking a transition in the patient population dynamics. Children (Dominant) vs. Adults (Emerging) The 'Children' segment in the Spain Allergy Immunotherapy Market is characterized by its large size, driven by pediatric allergies that often require specialized treatment approaches. This demographic is growing as more parents seek proactive ways to manage their children’s allergic conditions. Conversely, the 'Adults' segment, though currently smaller, is rapidly emerging as a result of increasing lifestyle-related allergies and a greater public awareness about available treatments. Adults are now seeking out immunotherapy options more frequently, spurred by recommendations from healthcare providers and a shift towards preventative healthcare practices. This dynamic presents an opportunity for growth, as healthcare strategies adapt to meet the evolving needs of both these important demographics. ### By Treatment Duration: Medium Term (Largest) vs. Long Term (Fastest-Growing) In the Spain Allergy Immunotherapy Market, the treatment duration segment exhibits diverse distribution patterns, with Medium Term therapies being the largest segment. This segment captures a significant share of the market, driven by the increasing adoption of effective treatment protocols that offer rapid relief. Long Term therapies, while smaller in market share, are gaining traction as patients look for sustainable solutions against allergies, thus positioning it as the fastest-growing segment in the market. Medium Term (Dominant) vs. Long Term (Emerging) The Medium Term treatment segment stands out as a dominant force in the Spain Allergy Immunotherapy Market, appealing to patients seeking a balanced approach to allergy management. These therapies typically span several months, allowing sufficient time for patients to build immunity. On the other hand, Long Term therapies are emerging as a noteworthy alternative, designed for ongoing management of allergy symptoms. They cater to patients prioritizing long-lasting relief and preventive measures, thus gaining popularity. The increasing awareness about chronic allergy management is propelling Long Term therapies into a competitive position alongside Medium Term options. ## Competitive Benchmarking The Spain Allergy Immunotherapy Market is characterized by a dynamic competitive landscape, driven by increasing prevalence of allergic conditions and a growing awareness of immunotherapy as a viable treatment option. Key players such as ALK-Abello (DK), Stallergenes Greer (FR), and Merck Group (DE) are actively shaping the market through strategic initiatives focused on innovation and regional expansion. ALK-Abello (DK) has positioned itself as a leader in the sector by investing heavily in research and development, particularly in sublingual immunotherapy products, which are gaining traction among patients seeking less invasive treatment options. Meanwhile, Stallergenes Greer (FR) emphasizes its commitment to personalized medicine, tailoring its immunotherapy solutions to meet the specific needs of patients, thereby enhancing treatment efficacy and patient satisfaction. The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The market appears moderately fragmented, with several players vying for market share, yet the influence of major companies is palpable. This competitive structure fosters innovation, as companies strive to differentiate their offerings through advanced technologies and improved patient outcomes. In January 2026, Merck Group (DE) announced a strategic partnership with a leading biotechnology firm to co-develop a novel immunotherapy treatment targeting specific allergens. This collaboration is expected to leverage both companies' expertise in immunology and biotechnology, potentially accelerating the development timeline and enhancing the therapeutic profile of the new treatment. Such partnerships may signify a shift towards more collaborative approaches in the industry, where shared resources and knowledge can lead to groundbreaking advancements. In December 2025, ALK-Abello (DK) launched a new digital platform aimed at improving patient engagement and adherence to immunotherapy regimens. This initiative underscores the growing importance of digital transformation in healthcare, as companies seek to enhance patient experiences and outcomes through technology. By integrating digital tools into their treatment protocols, ALK-Abello (DK) may not only improve patient compliance but also gather valuable data to inform future product development. In November 2025, Stallergenes Greer (FR) expanded its manufacturing capabilities in Spain, investing €10 million in a new facility designed to increase production capacity for its immunotherapy products. This expansion reflects the company's commitment to meeting rising demand and underscores the importance of supply chain reliability in the current market. By enhancing local production, Stallergenes Greer (FR) may also mitigate potential disruptions and improve its responsiveness to market needs. As of February 2026, the competitive trends in the Spain Allergy Immunotherapy Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. The competitive landscape is likely to evolve, with a shift from price-based competition towards differentiation through technology, innovative treatment solutions, and robust supply chain management. This transition may ultimately lead to improved patient outcomes and a more sustainable market environment. ## Recent News & Developments _In recent months, the Spain Allergy Immunotherapy Market has seen significant developments, particularly with the increased focus on environmental allergies and the government’s investment in healthcare innovation. In October 2023, Stallergenes Greer announced the expansion of its allergy immunotherapy production facility in Spain to meet rising demand, supporting local manufacturing and job creation. Additionally, in September 2023, Regeneron Pharmaceuticals and Novartis AG collaborated on a new treatment protocol aimed at enhancing the effectiveness of immunotherapy for allergic patients. In terms of mergers and acquisitions, MediFleur was reported to have acquired certain assets related to allergy diagnostics from Allergopharma GmbH & Co. KG in August 2023, enhancing their market position in Spain. Moreover, the market is witnessing growth, propelled by an increase in allergy prevalence among the Spanish population, particularly in urban areas, leading to heightened awareness and consumption of immunotherapy treatments. Recent trends indicate a consistent rise in market valuation, with companies like Merck KGaA and GSK exploring partnerships to innovate in allergen-specific immunotherapy. Overall, the market is evolving, reflecting a stronger emphasis on tailored therapeutic solutions for allergy sufferers in Spain._ ## Report Scope Report Scope: | Report Attribute/Metric Source: | Details | | --- | --- | | MARKET SIZE 2018 | 133.0(USD Million) | | MARKET SIZE 2024 | 142.75(USD Million) | | MARKET SIZE 2035 | 356.88(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.687% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | MARKET FORECAST PERIOD | 2025 - 2035 | | HISTORICAL DATA | 2019 - 2024 | | MARKET FORECAST UNITS | USD Million | | KEY COMPANIES PROFILED | Stallergenes Greer, MediFleur, Vaccinex, Boehringer Ingelheim, Romer Labs, Novartis AG, Astellas Pharma Inc., Regeneron Pharmaceuticals, Dr. Reddy's Laboratories, Anergis SA, Biocryst Pharmaceuticals, Merck KGaA, Allergopharma GmbH & Co. KG, GSK | | SEGMENTS COVERED | Type, Product, Indication, Patient Type | | KEY MARKET OPPORTUNITIES | Rising prevalence of allergies, Increased investment in R&D, Growing awareness of immunotherapy benefits, Advancements in treatment technologies, Expansion of telehealth services | | KEY MARKET DYNAMICS | Rising allergy prevalence, Increasing awareness of treatments, Growth in personalized medicine, Government support and regulations, Innovative product development | | COUNTRIES COVERED | Spain | ## Frequently Asked Questions **Q: What is the current valuation of the Spain Allergy Immunotherapy Market?** A: As of 2024, the market valuation was 79.24 USD Million. **Q: What is the projected market size for the Spain Allergy Immunotherapy Market by 2035?** A: The market is projected to reach 213.56 USD Million by 2035. **Q: What is the expected CAGR for the Spain Allergy Immunotherapy Market during the forecast period?** A: The expected CAGR for the market from 2025 to 2035 is 9.43%. **Q: Which application segment holds the highest valuation in the Spain Allergy Immunotherapy Market?** A: The Allergic Rhinitis segment had a valuation of 86.78 USD Million in 2024. **Q: What are the key types of immunotherapy in the Spain Allergy Immunotherapy Market?** A: The key types include Subcutaneous, Sublingual, Oral, and Intranasal Immunotherapy. **Q: How did the valuation of Sublingual Immunotherapy change from 2024 to 2035?** A: Sublingual Immunotherapy is expected to grow from 25.0 USD Million in 2024 to 70.0 USD Million by 2035. **Q: What demographic segment is projected to have the highest market valuation?** A: The Adults demographic segment is projected to grow from 35.0 USD Million in 2024 to 90.0 USD Million by 2035. **Q: Which companies are considered key players in the Spain Allergy Immunotherapy Market?** A: Key players include Allergopharma, Anergis, ALK-Abello, and Boehringer Ingelheim. **Q: What is the expected growth trend for the Insect Allergy segment in the coming years?** A: The Insect Allergy segment is projected to increase from 11.68 USD Million in 2024 to 28.74 USD Million by 2035. **Q: What treatment duration segment is anticipated to show significant growth?** A: The Maintenance Therapy segment is expected to grow from 19.24 USD Million in 2024 to 53.56 USD Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/spain-allergy-immunotherapy-market-56299*